David Ricks, Eli Lilly CEO (Photographer: David Paul Morris/Bloomberg via Getty Images)
October 6, 2022 02:54 PM EDT
Pharma
Marketing

Eli Lil­ly hits the gas on tirzepatide in obe­si­ty, nabs rolling sub­mis­sion for po­ten­tial block­buster in­di­ca­tion

Beth Snyder Bulik

Senior Editor

In the al­ready buzzy obe­si­ty drug mar­ket, Eli Lil­ly is the lat­est news­mak­er, nab­bing a fast-track des­ig­na­tion and rolling re­view from the FDA on Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times